Information  X 
Enter a valid email address

Circassia Grp PLC Ord 0.08P (CIR)

Related News

17-Mar-2017 07:30 AM

Circassia collaboration with AstraZeneca

Circassia Pharmaceuticals has reached agreement with AstraZeneca to enter into a collaboration and secure certain US commercial rights to two chronic obstructive pulmonary disease products, Tudorza and Duaklir, for a maximum total consideration of US$230m
24-Feb-2017 08:20 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today reaffirms its add investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 150p (from 160p). Story provided by StockMarketWire.com...
04-Jan-2017 10:50 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc

JP Morgan Cazenove today downgrades its investment rating on Circassia Pharmaceuticals Plc (LON:CIR) to neutral (from overweight) and cut its price target to 105p (from 140p). Story provided by StockMarketWire.com...
16-Dec-2016 02:55 PM

Circassia non-exec steps down

Circassia Pharmaceuticals' non-executive director Cathrin Petty has stepped down from the board after nearly seven years as a member. Chairman Dr Francesco Granata said : "On behalf of the Board, I would like to thank Cathrin for her significa
28-Sep-2016 09:20 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc

JP Morgan Cazenove today reaffirms its overweight investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 140p (from 170p). Story provided by StockMarketWire.com...
27-Sep-2016 11:10 AM

Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc

Numis today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 150p. Story provided by StockMarketWire.com...
27-Sep-2016 07:49 AM

Circassia revenues rise

Circassia Pharmaceuticals' revenues increased to £11.1 million (H1 2015: £0.6 million). R&D expenditure rose to £25.1 million (H1 2015: £18.4 million) including £13.8 million on allergy and the underlying loss increased
21-Jun-2016 12:10 PM

Broker Forecast - Stifel issues a broker note on Circassia Pharmaceuticals Plc Ord 0.08p

Stifel today downgrades its investment rating on Circassia Pharmaceuticals Plc Ord 0.08p (LON:CIR) to hold (from buy). Story provided by StockMarketWire.com...
21-Jun-2016 09:50 AM

Broker Forecast - RBC Capital Markets issues a broker note on Circassia Pharmaceuticals Plc Ord 0.08

RBC Capital Markets today downgrades its investment rating on Circassia Pharmaceuticals Plc Ord 0.08p (LON:CIR) to sector performer (from top pick) and cut its price target to 105p (from 430p). Story provided by StockMarketWire.com...
21-Jun-2016 09:30 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc Ord 0.08p

JP Morgan Cazenove today reaffirms its overweight investment rating on Circassia Pharmaceuticals Plc Ord 0.08p (LON:CIR) and cut its price target to 170p (from 410p). Story provided by StockMarketWire.com...
21-Jun-2016 08:00 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc Ord 0.08p

Peel Hunt today downgrades its investment rating on Circassia Pharmaceuticals Plc Ord 0.08p (LON:CIR) to add (from buy) and cut its price target to 160p (from 509p). Story provided by StockMarketWire.com...
19-May-2016 09:00 AM

Circassia resolutions passed at AGM

Circassia Pharmaceuticals has confirmed that all resolutions proposed at its annual general meeting yesterday were passed. At 9:00am: (LON:CIR) Circassia Pharmaceuticals Plc Ord 0.08p share price was -5.15p at 261.65p Story provided by StockMarketW
11-Mar-2016 11:30 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc Ord 0.08p

Peel Hunt today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc Ord 0.08p (LON:CIR) and cut its price target to 450p (from 460p). Story provided by StockMarketWire.com...
11-Mar-2016 07:28 AM

Circassia losses rise

Circassia Pharmaceuticals posts a loss of GBP50m for the year to the end of December - up from GBP35.1m in 2014. Pre-tax losses rose to GBP62.8m from GBP44.0m last time. The group reports robust revenue growth since acquisitions to £10.8 million (2014:
24-Nov-2015 07:54 AM

Circassia gets approval of fluticasone

Circassia Pharmaceuticals has announced the positive outcome of the European Decentralised Procedure (DCP) for the company's fluticasone propionate pressurised metered dose inhaler (pMDI) generic equivalent of GlaxoSmithKline's FLIXOTIDE pMDI fo
27-Oct-2015 07:51 AM

Circassia sees considerable progress

Circassia Pharmaceuticals reports considerable progress following the completion of recent acquisitions, with a number of important achievements across every part of the newly-enlarged business. Circassia markets its NIOX asthma management products dir
20-Jul-2015 04:27 PM

Circassia schedules interims

Circassia Pharmaceuticals will announce its interim results for the six months ended 30 June on 28 July. At 4:27pm: (LON:CIR) Circassia Pharmaceuticals Plc Ord 0.08p share price was -1.75p at 297.25p Story provided by StockMarketWire.com...
21-May-2015 09:19 AM

Circassia resolutions passed at AGM

Circassia Pharmaceuticals has confirmed that all the resolutions proposed at its annual general meeting yesterday were passed. At 9:19am: (LON:CIR) Circassia Pharmaceuticals Plc Ord 0.08p share price was -1.37p at 286.63p Story provided by StockMarke
15-May-2015 07:41 AM

Circassia to acquire Aerocrine and Prosonix

Circassia Pharmaceuticals intends to make an all cash offer to acquire Aerocrine, a Swedish listed company focused on the development and commercialisation of medical diagnostic products for use in the diagnosis and management of patients with asthma, for
09-Feb-2015 10:37 AM

New director at Circassia Pharmaceuticals

Circassia Pharmaceuticals (LSE: CIR), a specialty biopharmaceutical company focused on allergy, has appointed Lota S Zoth as a non-executive director. Ms Zoth has significant financial experience gained in a number of global public companies. Most rece
28-Jan-2015 08:34 AM

Circassia schedules FY results

Circassia Pharmaceuticals will announce its preliminary results for the year ended 31 December on 26 February. At 8:34am: (LON:CIR) Circassia Pharmaceuticals Plc Ord 0.08p share price was +0.38p at 257.38p Story provided by StockMarketWire.com...
08-Jan-2015 08:22 AM

Circassia completes recruitment for cat allergy study

Circassia Pharmaceuticals has completed recruitment into the pivotal phase III study of its cat allergy treatment, Cat-SPIRE. When recruitment closed on 31 December, 1,409 subjects had been randomised into the study. The total recruited exceeds the
11-Nov-2014 09:32 AM

Circassia on track to meet operational goals

Circassia Pharmaceuticals says it is is well positioned and on track to continue meeting its operational goals. By the end of 2014, the company anticipates completing recruitment into its phase III Cat-SPIRE study (CP007), and completing its Ragweed-S
29-Jul-2014 09:53 AM

Circassia operating losses rise

Circassia Pharmaceuticals posts an operating loss of £19.5m for the six months to the end of June. This was £9.5m higher than a year ago and reflects the increase in the number of clinical trials and more advanced stage of product development across
13-Jun-2014 07:52 AM

Circassia encouraged by study results

Circassia Pharmaceuticals has announced positive top-line results from a two-year follow-up of a phase IIb clinical study of HDM-SPIRE, a house dust mite allergy product candidate based on its proprietary ToleroMune platform technology. The phase IIb tw
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t